{"id":"NCT01071915","sponsor":"Ferring Pharmaceuticals","briefTitle":"Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer","officialTitle":"An Open-label, Multi-Centre Trial, Bridging Efficacy and Safety of Degarelix One-Month Dosing Regimen in Korean Patients With Prostate Cancer Requiring Androgen Ablation Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2010-02-19","resultsPosted":"2013-02-12","lastUpdate":"2013-02-12"},"enrollment":157,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Degarelix 240/80 mg","otherNames":["FE200486","FIRMAGON"]}],"arms":[{"label":"Degarelix 240/80 mg","type":"EXPERIMENTAL"}],"summary":"This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.","primaryOutcome":{"measure":"Cumulative Probability of Testosterone at Castrate Level (â‰¤0.5 ng/mL) From Day 28 to Day 196","timeFrame":"Day 28 to Day 196","effectByArm":[{"arm":"Degarelix 240/80 mg","deltaMin":96.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":11,"countries":["South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":156},"commonTop":["Injection site pain","Hyperhidrosis","Constipation","Injection site erythema","Upper respiratory tract"]}}